Holen Sie sich die Stockscreener-App
313.41
1.16%
-3.82
Handel nachbörslich:
313.41
Schlusskurs vom Vortag:
$317.23
Offen:
$319
24-Stunden-Volumen:
820.42K
Relative Volume:
0.54
Marktkapitalisierung:
$41.57B
Einnahmen:
$3.71B
Nettoeinkommen (Verlust:
$313.75M
KGV:
138.86
EPS:
2.2571
Netto-Cashflow:
$465.38M
1W Leistung:
-2.22%
1M Leistung:
-0.27%
6M Leistung:
-32.70%
1J Leistung:
+29.70%
1-Tages-Spanne:
$309.92
$319.50
1-Wochen-Bereich:
$309.61
$326.18
52-Wochen-Spanne:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.35 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.82 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.09 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
siRNA Therapeutics Market Poised for Rapid Growth to US$ 12.38 - openPR.com
Why Alnylam Pharmaceuticals Stock Was Soaring on Monday - AOL.com
Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Atika Capital Management LLC - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Lifted by WINTON GROUP Ltd - MarketBeat
Legal & General Group Plc Has $404.83 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
How Investors May Respond To Alnylam (ALNY) Expanding Cardiovascular RNAi Targets Through Tenaya Collaboration - simplywall.st
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Benzinga
Capital Research Global Investors Boosts Holdings in Alnylam Pharmaceuticals - National Today
Alnylam to Webcast TTR Investor Webinar - Business Wire
Capital Research Global Investors Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Capital World Investors - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Raised by Capital International Inc. CA - MarketBeat
Swiss National Bank Has $171.37 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Holdings Raised by Jefferies Financial Group Inc. - MarketBeat
Alnylam Pharmaceuticals grants performance-based equity award to CEO - Investing.com Nigeria
12,658 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Fieldview Capital Management LLC - MarketBeat
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Alnylam nabs key additional indication for Amvuttra - MSN
Alnylam targets 25% revenue CAGR through 2030 amid AMVUTTRA launch momentum and pipeline expansion - MSN
Korea Investment CORP Grows Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Rhenman & Partners Asset Management AB Has $14.54 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Partnership With Tenaya Therapeutics - simplywall.st
Alnylam Tenaya Cardiovascular RNAi Pact And What It Means For Valuation - Yahoo Finance
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness - Yahoo Finance
ALNYLAM PHARMACEUTICALS Executives Sell Shares - TradingView
Is It Time To Revisit Alnylam Pharmaceuticals (ALNY) After Recent Share Price Pullback - simplywall.st
Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - bioworld.com
Tenaya Therapeutics inks $1 billion-plus research deal with Alnylam - The Pharmaletter
Victory Capital Management Inc. Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal - Pharmaceutical Technology
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs - Yahoo Finance
Tenaya Therapeutics Stock Jumps After New Alnylam Deal - Sahm
Alnylam Updates Hypertension Pipeline And AMVUTTRA Access Shape Valuation View - Sahm
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Responsive Playbooks and the ALNY Inflection - Stock Traders Daily
Tenaya To Evaluate Genetic Cardiovascular Targets For Alnylam - Citeline News & Insights
Alnylam board creates $18M incentive award to keep CEO through 2029 - The Business Journals
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics - Investing News Network
Tenaya wins support from Alnylam in cardio disease pact - Endpoints News
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments - marketscreener.com
Tenaya Therapeutics Signs Potential $1.13 Billion Deal With Alnylam - marketscreener.com
Alnylam Pharmaceuticals (ALNY) Forms Partnership for Cardiovascu - GuruFocus
Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development - PR Newswire
Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration - TipRanks
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - Seeking Alpha
Tenaya Therapeutics enters into research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapeutics - marketscreener.com
Tenaya Therapeutics Enters into Research Collaboration with - GlobeNewswire
Focus Partners Advisor Solutions LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
CI Investments Inc. Buys 3,109 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Canada’s AMVUTTRA Reimbursement Tailwind Altering The Investment Case For Alnylam Pharmaceuticals (ALNY)? - Yahoo Finance
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Garg Pushkal | EVP Chief R&D |
Mar 04 '26 |
Sale |
323.08 |
2,309 |
745,984 |
21,097 |
| Greenstreet Yvonne | Chief Executive Officer |
Mar 04 '26 |
Sale |
323.08 |
2,933 |
947,581 |
95,695 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Mar 04 '26 |
Sale |
323.08 |
2,468 |
797,351 |
61,805 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Mar 04 '26 |
Sale |
323.08 |
2,309 |
745,984 |
34,297 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 05 '26 |
Sale |
323.98 |
658 |
213,177 |
20,569 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 04 '26 |
Sale |
323.08 |
633 |
204,508 |
21,227 |
0.44%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):